Inhibrx Reports on Financial Developments
Inhibrx Biosciences, Inc. (NASDAQ: INBX) has recently presented its financial outcomes for the latest quarter. This follows a transformative period, including the successful divestiture of its INBRX-101 therapy to Sanofi. Now, Inhibrx focuses on its ongoing clinical programs aimed at providing innovative solutions in disease treatment.
Recent Milestones in Clinical Trials
Positive Outcomes from Ongoing Studies
As part of their latest corporate updates, Inhibrx highlighted the success of the registrational trial for their therapy candidate, ozekibart (INBRX-109), specifically in treating chondrosarcoma. This trial showed promising topline results, indicating a significant improvement in patient outcomes compared to placebo.
Expansion of Clinical Cohorts
In addition to the advancements in chondrosarcoma, the company provided updates on their expansion cohorts for colorectal cancer and Ewing sarcoma. Early data from these studies suggest a strong response rate in patient groups that are usually challenging to treat. Inhibrx aims to submit a biologics license application to the FDA in the upcoming quarters, looking for rapid progression towards bringing these therapies to market.
Financial Overview of the Third Quarter
Cash Position and Expenses
As of the end of the third quarter, Inhibrx reported cash and cash equivalents amounting to $153.1 million, marking a decrease from $186.6 million at the end of June. This decline is attributed to operational expenses, mainly stemming from research and development activities and adjustments in workforce size.
Research and development expenses for this quarter were noted at $28.5 million, a decrease from $38.9 million compared to the same period last year. This reduction reflects fewer manufacturing activities handled by their contract development and manufacturing organizations, as well as a streamlined team.
Administrative Expenses and Loss Report
Furthermore, the general and administrative expenses decreased to $5.3 million in Q3, down from $7.9 million in the previous year. This reduction was largely due to the resolution of legal matters and fewer personnel-related costs. However, the company did report a net loss of $35.3 million this quarter, which translates to $2.28 per share, an improvement compared to a net loss of $43.9 million or $2.84 per share during the same quarter last year.
About Inhibrx Biosciences
Inhibrx is at the forefront of biopharmaceutical innovation, specializing in the development of biologic therapeutic candidates. With a focus on tailored protein engineering solutions, Inhibrx utilizes its proprietary platforms to meet the challenges presented by complex diseases. Following its establishment as a subsidiary in early 2024, the company aims to enhance the healthcare landscape with its pipeline, including ozekibart (INBRX-109) and INBRX-106, both designed to provide targeted therapeutic options.
Investor Contact Information
If you are interested in learning more about Inhibrx or wish to reach out for further inquiries, you can contact:
Kelly D. Deck
Chief Financial Officer
ir@inhibrx.com
858-795-4260
Frequently Asked Questions
What are the major recent positive outcomes Inhibrx has reported?
Inhibrx reported positive topline results from its trial of ozekibart for treating chondrosarcoma, indicating significant improvement in patient outcomes compared to placebo.
When does Inhibrx plan to submit its biologics license application?
Inhibrx plans to submit the biologics license application to the FDA in the second quarter of 2026.
How did Inhibrx’s cash position change over the last quarter?
The company's cash equivalents decreased to $153.1 million, down from $186.6 million due to operational expenses.
What was reported regarding Inhibrx's expenditures?
Research and development expenses were noted at $28.5 million, with a decrease in personnel costs contributing to reduced administrative expenses, totaling $5.3 million.
What was the net loss reported by Inhibrx for the last quarter?
Inhibrx reported a net loss of $35.3 million for the last quarter, translating to $2.28 per share, an improvement from the previous year's loss.
